文献速递认知障碍与痴呆

中年人群血小板聚集与阿尔茨海默病病理标志物的关联

Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study.
PubMed 文献 · Neurology · 2025-11-04

基于Framingham心脏研究,在382名无痴呆中年人中评估血小板聚集与淀粉样蛋白和tau PET摄取及MRI皮层厚度的关联。在ADP反应最低三分位组中,血小板聚集与楔前叶淀粉样蛋白及多个区域tau摄取正相关,与AD风险皮层厚度特征负相关。提示中年期血小板聚集已与AD病理影像标志物相关。

要点

  • 中年期血小板聚集与AD病理PET标志物存在非线性关联。
  • ADP反应最低三分位组中,血小板聚集与淀粉样蛋白和tau摄取正相关。
  • 血小板聚集与AD风险MRI皮层厚度特征负相关,提示神经退行性模式。

核心结论

  • 血小板聚集在中年期即与AD病理的PET和MRI标志物相关,支持进一步研究血小板介导机制在AD发病中的作用。

研究设计与样本

  • 横断面研究,纳入Framingham心脏研究中382名无痴呆中年人,平均年龄56±8岁,53%女性,血小板聚集用光透射聚集测定法评估。

主要发现

  • 在ADP反应最低三分位组中,血小板聚集反应与楔前叶淀粉样蛋白增加正相关(β=0.047,p=0.020)。
  • 在ADP反应最低三分位组中,血小板聚集反应与鼻周tau(β=0.077,p=0.012)、内嗅tau(β=0.066,p<0.020)、颞叶全局tau(β=0.063,p=0.031)和皮层tau(β=0.064,p=0.028)正相关。
  • 在次要结局分析(n=256)中,血小板聚集反应与基于MRI的AD风险皮层厚度特征负相关(β=-0.002,p<0.035)。

临床怎么用

  • 对于中年人群,血小板聚集功能可能作为AD病理早期风险的潜在评估指标,但尚需进一步验证。

局限性

  • 横断面设计无法确定因果关系,样本来自单一队列,血小板聚集评估与PET成像间隔约1.2-1.5年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Vascular dysfunction contributes to Alzheimer disease (AD) and related dementias (ADRDs), but the underlying mechanisms remain unclear. Previous studies link midlife hemostasis and platelet aggregation measures to late-life dementia risk. We aimed to determine whether platelet aggregation in midlife is associated with imaging markers of AD pathology. METHODS: In a cross-sectional study, we evaluated associations between platelet aggregation, measured by light transmission aggregometry, and amyloid (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET uptake in dementia-free, middle-aged adults from the Framingham Heart Study. Co-primary outcomes included amyloid and tau uptake in AD-vulnerable regions. We also examined an MRI-based cortical thickness signature of AD risk as a secondary outcome. We used multivariable regression models adjusted for demographic and clinical factors, considering potential nonlinear associations. RESULTS: Platelet aggregation response was evaluated in 382 participants (mean age 56 ± 8 years, 53% female) approximately 1.2-1.5 years before amyloid and tau PET imaging. MRI data used for the AD signature were acquired together with PET imaging or within several months. The aggregation response exhibited a nonlinear association with AD pathology. Among those in the lowest tertile of adenosine diphosphate (ADP) response, platelet aggregation response was positively associated with increased amyloid in the precuneus (β = 0.047, p = 0.020) and tau in the rhinal (β = 0.077, p = 0.012), entorhinal (β = 0.066, p < 0.020), temporal global (β = 0.063, p = 0.031), and cortical (β = 0.064, p = 0.028) regions. For the secondary outcome analysis (n = 256), platelet aggregation response was negatively associated with the MRI-based cortical thickness signature of AD risk (β = -0.002, p < 0.035), consistent with a neurodegenerative pattern. DISCUSSION: Our findings indicate that platelet aggregation is linked to PET and MRI markers of AD pathology as early as midlife. These findings support further investigation of platelet-mediated mechanisms in AD pathogenesis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ramos-Cejudo J, Beiser AS, Lu S, et al. Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study. Neurology. 2025. PMID: 41187307. doi:10.1212/WNL.0000000000214314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。